The pharmacodynamic biomarkers of SHetA2 to be evaluated in clinical trials include loss of cyclin D1 and Bcl-2 based on their down-regulation in association with SHetA2 cancer inhibition activities in multiple animal models described above. This evidence concerns the gene CCND1 and cancer.